WO1993014114A1 - Peptide linkage unit comprising methylene phosphinic acid - Google Patents
Peptide linkage unit comprising methylene phosphinic acid Download PDFInfo
- Publication number
- WO1993014114A1 WO1993014114A1 PCT/US1993/000228 US9300228W WO9314114A1 WO 1993014114 A1 WO1993014114 A1 WO 1993014114A1 US 9300228 W US9300228 W US 9300228W WO 9314114 A1 WO9314114 A1 WO 9314114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- group
- oligopseudopeptide
- acid residue
- sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 114
- LBYWTNBGUBZKJM-UHFFFAOYSA-N OP(=C)=O Chemical compound OP(=C)=O LBYWTNBGUBZKJM-UHFFFAOYSA-N 0.000 title description 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 120
- 102000004580 Aspartic Acid Proteases Human genes 0.000 claims abstract description 65
- 108010017640 Aspartic Acid Proteases Proteins 0.000 claims abstract description 65
- 239000003112 inhibitor Substances 0.000 claims abstract description 49
- 239000000758 substrate Substances 0.000 claims abstract description 34
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 claims abstract description 24
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims description 80
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 71
- 102000004190 Enzymes Human genes 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 39
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 39
- 229940088598 enzyme Drugs 0.000 claims description 39
- 108010016626 Dipeptides Proteins 0.000 claims description 34
- 108010038807 Oligopeptides Chemical group 0.000 claims description 27
- 102000015636 Oligopeptides Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- -1 quinolin-2- ylcarbonyl Chemical group 0.000 claims description 25
- 125000003277 amino group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 22
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical group O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 21
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 108090000783 Renin Proteins 0.000 claims description 14
- 102100028255 Renin Human genes 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 108090000284 Pepsin A Proteins 0.000 claims description 10
- 102000057297 Pepsin A Human genes 0.000 claims description 10
- 229940111202 pepsin Drugs 0.000 claims description 10
- 125000004437 phosphorous atom Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000003696 aspartic proteinase inhibitor Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 108090000258 Cathepsin D Proteins 0.000 claims description 5
- 102000003908 Cathepsin D Human genes 0.000 claims description 5
- 108090000746 Chymosin Proteins 0.000 claims description 5
- 108700033921 EC 3.4.23.20 Proteins 0.000 claims description 5
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 5
- KNYHAWKHFQRYOX-PYJNHQTQSA-N Val-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N KNYHAWKHFQRYOX-PYJNHQTQSA-N 0.000 claims description 5
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- GAMLAXHLYGLQBJ-UFYCRDLUSA-N Phe-Val-Tyr Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC1=CC=C(C=C1)O)C(C)C)CC1=CC=CC=C1 GAMLAXHLYGLQBJ-UFYCRDLUSA-N 0.000 claims description 4
- 229940080701 chymosin Drugs 0.000 claims description 4
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical group C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 claims description 4
- BZRGONFHSWNSQA-QMMMGPOBSA-N piperidine-2-carboxylic acid tert-butylamide Chemical group CC(C)(C)NC(=O)[C@@H]1CCCCN1 BZRGONFHSWNSQA-QMMMGPOBSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- MSFITIBEMPWCBD-ULQDDVLXSA-N Leu-Val-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MSFITIBEMPWCBD-ULQDDVLXSA-N 0.000 claims description 2
- UPZBXVBPICTBDP-TUAOUCFPSA-N (3s,4as,8as)-n-tert-butyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxamide Chemical group C1CCC[C@@H]2CN[C@H](C(=O)NC(C)(C)C)C[C@@H]21 UPZBXVBPICTBDP-TUAOUCFPSA-N 0.000 claims 3
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 claims 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 abstract description 12
- 230000007017 scission Effects 0.000 abstract description 12
- 230000007704 transition Effects 0.000 abstract description 9
- 235000001014 amino acid Nutrition 0.000 description 76
- 229940024606 amino acid Drugs 0.000 description 76
- 150000001875 compounds Chemical class 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 235000019833 protease Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 229920002616 peptidyl amide Polymers 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004881 Angiotensinogen Human genes 0.000 description 6
- 108090001067 Angiotensinogen Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 108010092114 histidylphenylalanine Proteins 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 5
- JJIHLJJYMXLCOY-UHFFFAOYSA-N N-acetyl-DL-serine Natural products CC(=O)NC(CO)C(O)=O JJIHLJJYMXLCOY-UHFFFAOYSA-N 0.000 description 5
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- PBVQWNDMFFCPIZ-ULQDDVLXSA-N His-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 PBVQWNDMFFCPIZ-ULQDDVLXSA-N 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-ZILXKATJSA-N (3R)-2,3-dihydroxybutanedioic acid Chemical compound OC([C@@H](O)C(O)=O)C(O)=O FEWJPZIEWOKRBE-ZILXKATJSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 2
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- LJTZPXOCBZRFBH-CIUDSAMLSA-N Ala-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N LJTZPXOCBZRFBH-CIUDSAMLSA-N 0.000 description 2
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZXURTNJNQDONAC-UHFFFAOYSA-N C(=O)=CC(C)(C)N Chemical compound C(=O)=CC(C)(C)N ZXURTNJNQDONAC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000000496 Carboxypeptidases A Human genes 0.000 description 2
- 108010080937 Carboxypeptidases A Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 2
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000002461 renin inhibitor Substances 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
- QWAXKHKRTORLEM-AZFKVOMOSA-N (2S)-N-[(2S,3R)-4-[(3S,4aS,8aR)-3-[(tert-butylamino)-oxomethyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[[oxo(2-quinolinyl)methyl]amino]butanediamide Chemical compound C([C@@H]([C@H](O)CN1C[C@@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-AZFKVOMOSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- DFVFTMTWCUHJBL-RQJHMYQMSA-N (3s,4r)-4-amino-3-hydroxy-6-methylheptanoic acid Chemical compound CC(C)C[C@@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-RQJHMYQMSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- HRWCWYGWEVVDLT-UHFFFAOYSA-N 2-amino-2,3-dihydro-1h-inden-1-ol Chemical compound C1=CC=C2C(O)C(N)CC2=C1 HRWCWYGWEVVDLT-UHFFFAOYSA-N 0.000 description 1
- KWOMLHIFHFWBSB-UHFFFAOYSA-N 2-azaniumyl-2-ethylbutanoate Chemical compound CCC(N)(CC)C(O)=O KWOMLHIFHFWBSB-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- GZLMFCWSEKVVGO-UHFFFAOYSA-N 3-azaniumyl-2-hydroxy-5-methylhexanoate Chemical compound CC(C)CC(N)C(O)C(O)=O GZLMFCWSEKVVGO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IASKXSDGBAVTOB-UHFFFAOYSA-N 3-methyl-2-sulfanylbutan-2-ol Chemical class CC(C)C(C)(O)S IASKXSDGBAVTOB-UHFFFAOYSA-N 0.000 description 1
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-Amino-3-hydroxy-6-methylheptanoic acid Natural products CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- 102000035101 Aspartic proteases Human genes 0.000 description 1
- 108091005502 Aspartic proteases Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108700033317 EC 3.4.23.12 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001673391 Entandrophragma candollei Species 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 101000579218 Homo sapiens Renin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- QRRBCZAFPPNLIP-UHFFFAOYSA-N O[PH2]=O.OP(O)=O Chemical compound O[PH2]=O.OP(O)=O QRRBCZAFPPNLIP-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000228129 Penicillium janthinellum Species 0.000 description 1
- AGYXCMYVTBYGCT-ULQDDVLXSA-N Phe-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O AGYXCMYVTBYGCT-ULQDDVLXSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- YTWNSIDWAFSEEI-RWMBFGLXSA-N Pro-His-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)O YTWNSIDWAFSEEI-RWMBFGLXSA-N 0.000 description 1
- GNADVDLLGVSXLS-ULQDDVLXSA-N Pro-Phe-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O GNADVDLLGVSXLS-ULQDDVLXSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- 241000208442 Sarracenia Species 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- NVSPJDGXKBDYIZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1=NC=CN2C=NN=C21 NVSPJDGXKBDYIZ-UHFFFAOYSA-N 0.000 description 1
- RMQXUAYCXLDUKS-WCCKRBBISA-N [N].OC(=O)[C@@H]1CCCN1 Chemical compound [N].OC(=O)[C@@H]1CCCN1 RMQXUAYCXLDUKS-WCCKRBBISA-N 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RXQNHIDQIJXKTK-UHFFFAOYSA-N azane;pentanoic acid Chemical group [NH4+].CCCCC([O-])=O RXQNHIDQIJXKTK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical class C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- XJJBXZIKXFOMLP-ZETCQYMHSA-N tert-butyl (2s)-pyrrolidine-2-carboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN1 XJJBXZIKXFOMLP-ZETCQYMHSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3241—Esters of arylalkanephosphinic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
- B60W40/00—Estimation or calculation of non-directly measurable driving parameters for road vehicle drive control systems not related to the control of a particular sub unit, e.g. by using mathematical models
- B60W40/08—Estimation or calculation of non-directly measurable driving parameters for road vehicle drive control systems not related to the control of a particular sub unit, e.g. by using mathematical models related to drivers or passengers
- B60W40/09—Driving style or behaviour
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16H—GEARING
- F16H59/00—Control inputs to control units of change-speed-, or reversing-gearings for conveying rotary motion
- F16H2059/003—Detecting or using driving style of a driver, e.g. for adapting shift schedules
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16H—GEARING
- F16H2312/00—Driving activities
- F16H2312/02—Driving off
Definitions
- the present invention relates to linkage units for joining peptide sequences and to the use of such linkage units for forming peptides and
- pseudopeptides including pseudopeptides that inhibit aspartic proteinase enzymes. More particularly, the invention relates to pseudopeptides that include a phosphinate methylene ammonium linkage (exploding transition state analog) in place of an amide bond at the position in a peptide sequence that is cleaved by aspartic proteinase enzymes.
- pseudopeptides that include a phosphinate methylene ammonium linkage (exploding transition state analog) in place of an amide bond at the position in a peptide sequence that is cleaved by aspartic proteinase enzymes.
- Peptide linkage units are employed in the construction of peptides.
- naturally occurring L-amino acids serve as peptide linkage units.
- various unnatural L-amino acids and a wide variety of D-amino acids may also serve as peptide linkage units.
- the peptide linkage unit need not employ a peptide bond to form the linkage.
- a number of pseudopeptides are disclosed and employed in the prior art as peptide linkage units.
- a peptide linkage unit may be employed to link two peptide sequences or may be employed at the terminal end of a peptide.
- the peptides lying on either side of a peptide linkage unit may be
- Peptide linkage units are employed in the construction of synthetic proteinase inhibitors.
- proteinase substrates include a proteinase binding or recognition region which flanks either side of the cleavage site. Accordingly, one class of synthetic proteinase inhibitor employs peptides having amino acid sequence homology with the binding or recognition regions of known proteinase
- peptide linkage unit may then be employed to link the two peptides together.
- the peptide linkage unit will be positioned at or near the cleavage site.
- Peptide linkage units which are resistant to proteolysis and which bind tightly to the active site of the proteinase are particularly useful in the construction of synthetic proteinase inhibitors.
- Aspartic proteinase enzymes (EC 3.4.23) are a family of related enzymes that cleave (hydrolyze) protein and polypeptide chains. These enzymes have isoelectric points on the acid side of neutrality and molecule masses ranging from 35,000-45,000 Daltons (D) for fungal enzymes and about 35,500 D for pepsin.
- Exemplary enzymes of this class include pepsin that is a mammalian gastric proteinase, cathepsin D that is the intracellular aspartic proteinase of the lysosomal system and whose level has been positively correlated with recurring breast cancers [Tandon et al., N. Eng. J. Med., 322:297 (1990)] and with amyloid formation in Alzheimer's plagues [Cataldo et al., Brain Res., 513:181 (1991)], renin that
- angiotensinogen to form angiotensin I
- chymosin previously called rennin
- Penicillopepsin a microbial enzyme from P. janthinellum is another member of this family
- nepenthesin the digestive proteinase of the pitcher plant is
- the HIV-1 virus also contains an aspartic protease. That enzyme is known to cleave the p17-p24 region of the Pr55 gag fusion protein. Moore et al., Biochem. Biophys. Res. Comm., 159:420 (1989).
- hydrolyzed The hydrolyzed peptide bond is typically between hydrophobic residues.
- a covalent bond is typically between hydrophobic residues.
- This family of enzymes forms an enzyme-substrate complex as is typical in enzyme-substrate reactions. Binding is often found to be a two-step process even through no covalent bonds are formed.
- inhibitors include polypeptides similar in sequence to a natural substrate of an enzyme that also include one or more D-amino acids in place of the naturally occurring L-amino acids.
- Another group of inhibitors contains the surrogate (3S,4R)-4-amino- 3-hydroxy-6-methylheptanoic acid, designated AHMHA or statine (Sta), in place of the two residues between which the hydrolysis occurs, such as Leu and Ala.
- statine-containing group of inhibitors were first found in the naturally occurring inhibitor known as pepstatin A that inhibits each of pepsin cathepsin D with a K i value of about 10 -10 -10 -11 M and renin with a K i value of 10 -6 M.
- Inhibitors containing a hydroxyethylamine moiety as a peptide bond surrogate have also been reported. Inhibitors of particular interest herein that contain the hydroxyethylamine surrogate bond have been
- penicillopepsin were reported. Those inhibitors were pseudopeptides that included a phosphorus-containing bond in place of the scissile amide bond that would normally be cleaved by those enzymes.
- a phosphonate group has the linkage -P(O) (OH)O-, in which the shown valence of the phosphorus atom is bonded to a carbon and takes the place of an amide carbonyl group, and the free valence of the oxygen is bonded to a carbon atom, taking the place of the amido -NH- group.
- a phosphinate group has the linkage -P(O)(OH)-, so that the phosphorus atom is bonded to two carbon atoms.
- a phosphinamide has the linkage -P(O)(NH 2 )-, so that the phosphorus atom is bonded to two carbon atoms and includes an -NH 2 side group.
- the present invention contemplates a linkage unit for joining two peptide sequences, i.e. an amino terminal peptide sequence and a carboxyl terminal peptide sequence.
- the linkage unit comprising a dipeptide having a first amino acid residue (aa 1 ), a second amino acid residue (aa 2 ), and an "exploded" linkage between the first and second amino acid residues.
- the first amino acid residue is conventional except that it lacks a backbone carbonyl group and has, instead, a
- phosphinic acid group i.e. (aa 1 -POOH-).
- the second amino acid residue is also conventional and includes a backbone amino group, i.e. (-NR-aa 2 ), where R is H or C.
- the exploded linkage between the first and said second amino acid residues lacks but has, instead, a methylene group.
- the methylene group is bonded both to the phosphinic acid group of the first amino acid residue and to the backbone amino group of the second amino acid residue.
- the resultant phosphinic acid methylene amino bonds form an
- this "exploded" linkage can be represented by the following formula, viz.:
- the phosphinic acid and amino groups are to zwitterionic phosphinate and ammonium groups.
- the "exploded" linkage can be represented by the following formula, viz.:
- the above dipeptide constitutes a linkage unit which can be employed to link amino acid residues or sequences.
- the first amino acid residue (aa 1 ) within the dipeptide may include a bondable amino group which can be employed to form a peptide linkage with the carboxyl group of a "flanking" amino acid or with the carboxyl group of an amino terminal peptide sequence.
- the second amino acid residue (aa 2 ) within the dipeptide may include a bondable carboxyl group which can be employed to form a peptide linkage with the amino group of a "flanking" amino acid or with the amino broup of a carboxyl terminal peptide sequence.
- the resultant oliogo or poly-peptide is improved because it includes the linkage unit with its dipeptide having an "exploded" methylene linkage.
- exploded methylene linkage may be positioned between two peptide sequences, i.e. the amino acids
- the present invention also contemplates an inhibitor for an aspartic proteinase enzyme.
- the inhibitor is a pseudopeptide that includes a
- a pseudopeptide aspartic proteinase inhibitor typically has a length of 3 to about 15 amino acid residues, preferably 4 to about 10 residues, and contains a P 1 to P 1 ' bond that is constituted by a phosphinate methylene ammonium linkage in which the phosphorus atom is bonded to P 1 in place of the carbonyl carbon atom and methylene amine replaces the amide nitrogen of a peptide bond.
- a particularly preferred pseudopeptide of the invention can be represented by the zwitterionic formula
- oligopeptide containing a sequence of up to about ten amino acid residues
- a is zero, one or two so that zero, one or two hydrogens are present, respectively;
- Xaa is a surrogate amino acid residue having an amino acid side chain
- X 2 is an amino acid residue or oligopeptide containing a sequence of up to about ten amino acid residues
- Z is selected from the group consisting of NH 2 , NH-C 1 -C 6 acyl, OH, O-C 1 -C 6 alkyl, NH-C 1 -C 6 alkyl and 2-amidoindanol; and R 1 is selected from the group consisting of hydrogen, C 1 -C 6 acyl, trifluoroacetyl, quinolin-2- ylcarbonyl and t-BOC.
- a pseudopeptide preferably competitively
- an aspartyl proteinase inhibits the in vitro activity of an aspartyl proteinase with an inhibition constant of about 10 -6 to about 10 -11 M, and more preferably about 10 -8 to about 10 -11 M.
- Xaa has the side chain of a Leu, Tyr or Phe residue, and the amino-terminal residue of X 2 is Tyr, Leu, Val, Met, Pro, Ala or Phe.
- X 2 can also be a piperidine-2 (s) carboxyl group (PIC) or a (4aS, 8aS)-decahydroisoquinoline-3 (S) carboxyl group (DIQ), or an amide or ester thereof.
- a pharmaceutical composition that contains an above pseudopeptide in an amount sufficient to inhibit an aspartic proteinase dissolved or dispersed in a physiologically tolerable carrier or diluent is also contemplated.
- an aspartic proteinase is admixed in an aqueous medium with the enzyme and a substrate for the enzyme to form an inhibition mixture.
- the inhibition mixture so formed is
- a compound of the invention is depicted using the "psi bracket" ( ⁇ [ ] ) nomenclature for oligopeptide analogs having backbone modification described in Spatola, Chemistry and Biochemistry of: Amino Acids, Peptides and Proteins. Weinstein, ed., Volume 7, chapter 5, Marcel Dekker, Inc., New York, pages 267- 357 (1983).
- brackets indicates that the specified structural group within the brackets replaces the peptidyl amide bond
- the word "surrogate” refers to an unnatural replacement for a naturally occurring entity, so that a psi-bracketed structural group is a surrogate for the peptidyl amide bond as is the residue containing the bond surrogate a surrogate for an amino acid residue;
- a "pseudodipeptide” is a modified dipeptide structural unit that contains a surrogate bond(s) or amino acid residue (s);
- a compound of this invention contains a PO(OH)CH 2 group in place of a petidyl amide carbonyl group.
- Such a compund thus contains a pentavalent
- tetrahedral phosphorus atom as part of a phosphinic acid methylene amine that is written V[PO(OH)CH 2 NH a ] as a surrogate for a peptidyl amide bond. That linkage is written ⁇ [PO 2 -CH 2 NH a + ] as a phosphinate methylene ammonium in zwitterionic form.
- the linkage can also exist as ⁇ [PO 2 HCH 2 NH + ], ⁇ [PO(OH)CH 2 NH 2 + ], ⁇ [PO 2 - CH 2 N] and the like depending upon pH values and the amino acid residue of P 1 ', as discussed hereinafter.
- the peptidyl amide bond surrogate is usually referred to as a phosphinate methylene ammonium group or linkage.
- oligopeptide is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “oligopeptide” is used in its usual sense to mean a peptide containing ten or fewer amino acid residues. Similarly, the term “
- oligopseudopeptide refers to a pseudopeptide containing ten or fewer amino acid residues and surrogates therefor.
- a peptide substrate for a hydrolase enzyme is numbered in two directions from the point of hydrolytic cleavage.
- the amino acid residues of the dipeptide portion that is cleaved are numbered P 1 and P 1 ' such that after cleavage, the P 1 residue becomes the carboxy-terminal residue of one cleaved portion and the P 1 ' residue becomes the amino-terminal residue of the other portion.
- the remaining residues toward the carboxy-terminus of the P 1 '-containing portion are numbered P 2 ', P 3 ', P 4 ' ... and so on toward the
- the dipeptide portion of a hydrolase substrate oligopeptide that is cleaved is thus defined as P 1 - P 1 '.
- the Schechter and Berger nomenclature system is utilized whether or not the bond linking the P 1 and P 1 ' residues is a peptide bond or is capable of hydrolytic cleavage, and is therefore useful with pseudopeptides where P 1 -P 1 ' constitutes the before- defined pseudodipeptide that is not cleaved.
- the present invention relates to pseudopeptide compounds that reversibly bind to and competitively inhibit the activity of an aspartic proteinase.
- a contemplated oligopeptide analog inhibits that enzymatic activity in the presence of a substrate for the enzyme and is therefore a competitive inhibitor.
- a compound contemplated herein is referred to as a pseudopeptide because although most of the subunit amino acids are linked by peptidyl amide bonds, two such residues are linked by a peptidyl amide bond surrogate phosphinic acid methlene amine group
- the peptidyl amide bond surrogate is often referred to by the zwitterionic name.
- a contemplated pseudopeptide reversibly binds to an aspartic proteinase to form an enzyme-inhibitor complex.
- Such binding and complex formation are familiar to those skilled in enzyme kinetics, and are to be distinguished from the interactions of
- a contemplated pseudopeptide binds to (or is bound by) an aspartic proteinase, but does not chemically react with the enzyme.
- Phosphonamidate-containing compounds have been used as transition state analog inhibitors for metallopeptidases such as carboxypeptidase A, thermolysin and angiotensin converting enzyme (ACE). See, for example Rich, Peptidase Inhibitors.
- Metallopeptidases and serine proteinases act on their substrates in a different manner than do aspartic proteinases.
- the non- esterified phosphonamidates are unstable under the acid pH conditions at which aspartic proteinase enzymes typically act and are therefore poor
- the exploding transition state analog-containing pseudopeptides contemplated herein are stable at the acidic pH values at which aspartic proteinases act.
- a phosphinate methylene ammonium linkage of a compound described herein also can be viewed as an isostere of an amide hydrolysis transition state. It is thought that the phosphinate methylene ammonium linkage represents an isostere for the late
- transition state of amide hydrolysis i.e., an isostere to the hydrated enzyme-bound substrate whose carbonyl group/nitrogen atom bond is stretched almost to breaking and whose hydrated carbonyl group and nitrogen atom bear developing charges.
- Structural features of a phosphinate methylene ammonium linkage include: (a) positive and negative charges that mimic the developing charges for the hydrolysis of a peptide bond; (b) the phosphinate portion is an excellent representation of the acyl carbon that becomes tetrahedral in the hydrated transition state; (c) the methylene unit acts as a spacer separating the two charged heteroatoms by about 2.2 A, thus providing the "explosion" of the analog amide bond moiety; (d) this peptide bond surrogate is both acid and base stable as compared to phosphonate and phosphonamidate; and (e) the
- a phosphinate methylene ammonium group contemplated herein as a zwitterion is also electrically neutral (is free from net ionic charge) at pH values encountered in living organisms and as such contributes to passage of a pseudopeptide through cell membranes.
- a contemplated preferred pseudopeptide aspartic proteinase inhibitor can have a length of 3 to about 15, and more preferably 4 to about 10, amino acid residues and has a P 1 to P 1 ' bond surrogate that is constituted by a phosphinate methylene ammonium linkage (group) in which the phosphorus atom is bonded to (i) a carbon at P 1 in place of the carbonyl carbon atom of a peptide bond, and (ii) a methylene ammonium group (as a zwitterion) in place of the amido nitrogen atom of a peptide bond.
- Such an inhibitor typically inhibits the in vitro activity of an aspartic proteinase with an inhibition constant, K i , of about 10 -6 to about 10 -11 M.
- K i an inhibition constant
- the inhibition constant is readily ascertained in the presence of a usual, native substrate for the enzyme as discussed hereinafter.
- the residue length of a contemplated inhibitor is determined as if the P 1 -P 1 ' positions were linked by a peptide bond.
- the P 1 position surrogate residue is thus considered for this purpose to be an amino acid residue even though the carboxyl group normally present is replaced by a tetrahedral phosphorus- containing moiety.
- oligopeptide containing a sequence of up to about ten amino acid residues
- a is zero, one or two;
- Xaa is a surrogate amino acid residue having an amino acid side chain
- X 2 is an amino acid residue or oligopeptide containing a sequence of up to about ten amino acid residues
- Z is selected from the group consisting of NH 2 , NH-C 1 -C 6 acyl, OH, O-C 1 -C 6 alkyl, NH-C 1 -C 6 alkyl and 2-amidoindanol;
- R 1 is selected from the group consisting of hydrogen, C 1 -C 6 acyl, trifluoroacetyl, quinolin-2- ylcarbonyl and t-BOC.
- the subscript "a" adjacent to the hydrogen in the phosphinate methylene ammonium linkage surrogate peptide bond indicates the number of hydrogens
- surrogate is present as an amine rather than as an amide, and consequently can be protonated at
- the two unusual amino acids PIC and DIQ are also secondary amines so that "a" is zero or one for an oligopseudopeptide containing PIC of DIQ.
- the amino group of the surrogate bond is usually depicted as protonated herein in view of the basicity of the amino group of the surrogate, and so "a" is usually one or two.
- the phosphinate- containing portion of the surrogate bond is normally deprotonated in aqueous solution at physiological pH values and those slightly acidic pH values at which aspartic proteinases usually function. That portion is thus illustrated as PO 2 -.
- the surrogate phosphinate methylene ammonium linkage is therefore sometimes shown herein as a zwitterion in which the phosphinate is deprotonated and negatively charged, and the amine is shown as protonated and positively charged.
- the zwitterionic and unionized forms are to be taken as equivalent. It is to be understood, however, that protonation of the phosphinate and amino portions can vary with the pH value of a medium in which a pseudopeptide is present, or from which it was obtained.
- a particularly preferred pseudopeptide has a length of 4 to about 10 amino acid residues, and competitively inhibits the in vitro activity of the aspartyl proteinase with an inhibition constant of about 10 -8 to about 10 -11 M.
- Exemplary C 1 -C 6 acyl groups of R 1 and Z include formyl, acetyl, propionyl, butanoyl, iso-butanoyl, isovaleryl (Iva), hexanoyl, cyclopentylcarbonyl and the like.
- a t-BOC group is a tertiary-butyloxy carbonyl group as is often used as a protecting group in solid phase peptide syntheses, and is utilized herein bonded to an amino-terminal amine or ⁇ -amino group of a lysine residue.
- An N-terminal quinolin-2- ylcarbonyl (QC) group is also contemplated.
- Exemplary C 1 -C 6 ; alkyl groups of Z include methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec- butyl, tert-butyl (t-butyl; tertiary-butyl, or t Bu), pentyl, 2-methylbutyl, cyclopentyl, hexyl,
- pseudopeptide is present as a carboxy-terminal C 1 -C 6 alkyl ester.
- the group Xaa is a surrogate amino acid residue having the side chain of an amino acid. Although Xaa can have any side chain of one of the twenty
- Xaa preferably has the side chain of a Leu, Tyr or Phe amino acid.
- the Xaa group is in the P 1 position of a contemplated pseudopeptide.
- Each of X 1 and X 2 can be an amino acid residue or an oligopeptide of up to about ten, and preferably up to about five amino acid residues.
- the sequences of X 1 and X 2 can contain any amino acid residues.
- amino-terminal residue of X 2 (the P 1 ' position residue) is selected from the group
- X 2 can also be a piperidine-2(s)carboxyl group (PIC) or a (4aS,8aS)-decahydroisoquinoline-3 (S) carboxyl group (DIQ). These X 2 moieties can be viewed as analogs of proline.
- the overall length of a pseudopeptide, aside from an R 1 or Z group, is 3 to about 15 amino acid residues, and more preferably 4 to about 10 amino acid residues.
- each of X 1 and X 2 can separately be up to about 10 amino acid residues in length, both cannot include 10 amino acid residues.
- X 1 can include 10 amino acid residues (occupying positions P 2 -P 11 of the sequence) and X 2 can include four residues (occupying positions P 1 '-P 4 ' of the sequence). X 2 can similarly include 10 residues with X 1 including 4 residues.
- mercaptan of cysteine carboxyl groups such as those of aspartic and glutamic acids, and the e-amino group of a lysine are typically absent from X 1 and X 2 sequences, and from Xaa group side chains.
- Those reactive side chains are also relatively hydrophilic. This absence of hydrophilic side chains is also a function of the active site of this family of enzymes exhibiting a preference for relatively hydrophobic side chains, particularly for the P 1 and P 1 '
- An amino acid residue of X 1 and X 2 or side chain of Xaa can be present in an oligopeptide analog sequence in either a D- or L-configuration, as is exemplified below wherein all residues are in the L-configuration unless preceded by a "D -".
- D- and L-amino acid residues contemplated for use in an oligopeptide analog, but modified and unusual amino acid residues, amines and carboxylic acids are also contemplated, particularly at or adjacent the amino- and carboxy-termini of an pseudopeptide.
- 2-dimethylglycine residue can be present at either or both termini, or a 2-aminoindanol can be amide- bonded to a carboxy-terminal residue to form a 2- amidoindanol group.
- a C 1 -C 6 acyl group as discussed previously such as 3-methylbutanoyl
- isovaleryl; Iva can be useful at the amino- terminus, whereas 3-methylbutylamine reacted at the carboxy-terminus to form a 3-methylbutylamide
- isoamylamide; Iaa can also be useful as can an aminovalaric acid forming a amylamide (Avl).
- the above terminal substituent groups and modified amino acid residues serve at least two functions. First, their presence removes ionic charge from the pseudopeptide to help facilitate passage through membranes. Second, they help protect the pseudopeptide from degradation by other
- proteinase and peptidase enzymes such as trypsin and carboxypeptidase A that are present in vivo and can otherwise cleave a pseudopeptide.
- a contemplated pseudopeptide binds to an
- polyprotein (substrate) that is reversibly bound by a given aspartic proteinase, except for the phosphonamidate ester linkage as is illustrated before.
- the K i value of a contemplated inhibitor can also be viewed relative to the dissociation constant of a usual substrate for the enzyme, as is angiotensinogen for renin.
- a contemplated inhibitor binds to its aspartic proteinase about 10 5 to about 10 6 times more tightly than does the usual substrate.
- the dissociation constant for the enzyme and its substrate is about 10 -3
- the dissociation constant for the same enzyme and a contemplated inhibitor is about 10 -8 to about 10 -9 .
- inhibitor sequences are utilized with different members of the aspartyl proteinase family.
- Each of the contemplated different sequences nevertheless contains a phosphinate methylene ammonium link between the P 1 and P 1 ' residues of the inhibitor.
- Table 1 below lists illustrative members of the aspartic proteinase enzyme family and exemplary, contemplated inhibitors form for each listed enzyme.
- Synthesis of a contemplated pseudopeptide is relatively straightforward inasmuch as most of the molecule's length is constituted by oligopeptides.
- One preferred method utilizes a first preprepared oligopeptide for the P 2 -containing portion (X 1 -Xaa) and a second preprepared oligopeptide for the P 1 '- containing portion (X 2 ). Those two portions are then joined to the phosphorus-containing segment to form the molecule.
- an aldehyde having the desired amino acid side chain is reacted with the
- diphenylmethylamine salt of hypophosphorous acid in reflexing dioxane The diphenylmethyl group could be subsequently cleaved using hydrobromic acid at 100°C for 45-120 minutes.
- the desired CBZ derivative can then be prepared using usual techniques. Those authors also reported resolving the CBZ blocked phosphonous acids by salt formation in refluxing ethanol with (+)- ⁇ -methylbenzylamine.
- oligopseudopeptide was carried out as outlined in Scheme 2 , and discussed below.
- the reaction was carried out in tetrahydrofuran (THF) at room temperature for about three hours to provide Compound 4 in about 65 percent yield.
- the CBZ group of Compound 4 was deprotected by hydrogenolysis over palladium on carbon at room temperature using a solvent of methanol/ethyl acetate and a reaction time of about three hours.
- That deprotection step was followed by removal of the phosphinic methyl ester by reaction in dry t- butylamine (t-BuNH 2 ) at about 40-50°C to provide the deblocked, heptapseudopeptide.
- Compound 1 can be resolved by salt formation using a usual amine resolving agent such as brucine or ⁇ -methylbenzylamine.
- the deprotected tetrapseudopeptide formed after removal of the CBZ group from Compound 4 can be resolved by salt formation using R-tartaric acid.
- the carboxy-terminus of a completed oligopseudopeptide inhibitor contains a free carboxylic acid, resolution can again be carried out with brucine.
- R-tartaric acid can be used for resoltuion.
- An oligopseudopeptide ester such as Compound 5 contains a second chiral center at the phosphorus atom due to the presence of the ester group so that Compound 5 exists as a pair of
- the before-described preprepared oligopeptides that constitute the X 1 and X 2 portions of an inhibitor pseudopeptide can be prepared by any well known method.
- the two blocked tripeptides used herein were prepared by standard solution reactions. Solid phase techniques pioneered by Merrifield are also useful. Both solution and solid phase syntehtic methods are well known by those skilled in the art.
- R 1 group that is a C 1 -C 6 acyl group can be added to the P 2 -containing peptide portion (X 1 -Xaa) while that peptide is on its synthesis resin or by addition of an N-acetyl blocked (Ac) amino acid during synthesis as was done here.
- a trifluoroacetyl or t-BOC group is preferably added after cleavage of the peptide from its synthesis resin.
- a Z group is preferably added to its
- the QC group can be added at the stage at which the acetyl group is added to a peptide using the acid halide or anhydride.
- a PIC-NH- t Bu or DIQ- NH- t Bu group can first be synthesized from their respective amino acids and then reacted with a phosphorus-containing compound such as Compound 3 as is shown in Scheme 2, above, instead of using the tripeptide ester shown in that scheme.
- a pharmaceutical composition is also provided.
- pseudopeptide of the invention as active agent dissolved or dispersed in a physiologically tolerable carrier or diluent.
- a pseudopeptide inhibitor is present in such a composition in an amount sufficient to inhibit the aspartic proteinase activity of a chosen aspartic proteinase (an effective inhibitory amount).
- a pharmaceutical composition is prepared by any of the methods well known in the art of pharmacy all of which involve bringing into association the pseudopeptide active agent and the carrier therefor.
- a pseudopeptide utilized in the present invention can be administered in the form of conventional pharmaceutical compositions.
- Such compositions can be formulated so as to be suitable for oral or parenteral administration, or as
- the agent is typically dissolved or dispersed in a physiologically tolerable carrier or diluent.
- a carrier or diluent is a material useful for administering the active compound and must be
- physiologically tolerable or “pharmaceutically acceptable” are used interchangeably and refer to molecular entities and compositions that do not produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a mammal.
- the physiologically tolerable carrier can take a wide variety of forms depending upon the preparation desired for
- active agent can be utilized, dissolved or dispersed in a liquid
- composition such as a sterile suspension or solution, or as isotonic preparation containing suitable preservatives.
- injectable media constituted by aqueous injectable buffered or unbuffered isotonic and sterile saline or glucose solutions, as well as water alone, or an aqueous ethanol solution.
- Additional liquid forms in which these compounds can be incorporated for administration include flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil, and the like, as well as elixirs and similar pharmaceutical vehicles. Exemplary further liquid diluents can be found in
- liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, pharmaceutically acceptable and metabolizable lipid capable of forming liposomes can be used.
- the present compositions in liposome form can contain stabilizers, preservatives, excipients, and the like in addition to the agent.
- the preferred lipids are the phospholipids and the phosphatidyl cholines
- An active agent pseudopeptide can also be used in compositions such as tablets or pills, preferably containing a unit dose of the compound. To this end, the agent (active ingredient) is mixed with
- tablets or pills can be laminated or otherwise compounded to provide unit dosage forms affording prolonged or delayed action.
- the pharmaceutical composition described herein can include, as
- ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
- the tablets or pills can also be provided with an enteric layer in the form of an envelope that serves to resist disintegration in the stomach and permits the active ingredient to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings including polymeric acids or mixtures of such acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate phthalate, and the like.
- a particularly suitable enteric coating comprises a styrene-maleic acid copolymer together with known materials that contribute to the enteric properties of the coating. Methods for producing enteric coated tablets are described in U.S. Patent 4,079,125 to Sipos, which is herein incorporated by reference.
- unit dose refers to physically discrete units suitable as unitary dosages for administration to warm blooded animals, each such unit containing a predetermined quantity of the agent calculated to produce the desired therapeutic effect in association with the pharmaceutically acceptable diluent.
- suitable unit dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing, and the like.
- a pseudopeptide of the invention is present in such a pharmaceutical composition in an amount effective to achieve the desired inhibition.
- a compound of the invention can be utilized in an amount sufficient to provide a
- an effective amount of a compound of the invention is about 0.1 to about 50 mg per kilogram of body weight or an amount sufficient to provide a concentration of about 0.01 to about 100 ⁇ g/mL to the bloodstream.
- composition as discussed before that contains an aspartic proteinase inhibiting amount of a before- discussed pseudopeptide is admixed in an aqueous medium with an aspartic proteinase in the presence of a substrate for the enzyme to form an inhibition mixture.
- the inhibition mixture is maintained for a time period sufficient for the inhibitor to inhibit the aspartic proteinase, typically five minutes to five hours.
- the inhibition reaction is typically followed spectrophotometrically.
- the aqueous medium in such a case is typically a buffer solution.
- Exemplary in vitro techniques are
- the aqueous medium is constituted by a body fluid such as blood, lymph, stomach fluid or the like, and inhibition of the enzyme is assayed by a body fluid
- Porcine stomach mucosa pepsin (Sigma Chemical Co.) is chromatographically purified and is dissolved and diluted immediately prior to use in a 0.1 M sodium acetate buffer at pH 3.5.
- a useful substrate is the octapeptide analog:
- renin concentration that inhibits 50 percent activity are preincubated with renin for about five minutes at 37°C.
- the substrate is then added and incubation is continued for about 10 minutes.
- the reaction is stopped by freezing the solution in a methanol/dry ice bath, and after thawing at 4°C, an aliquot is analyzed for angiotensin I by use of a commercial kit (NEN Research). The percent inhibition of the hydrolysis reaction is determined and an IC 50 value is calculated by regression analysis.
- MAP mean arterial pressure
- hypotensive drug such as captopril (at 1.0 mg/kg, iv) or the compound designated CGP 385-60A [Buhlmayer et al., J. Med. Chem., 31:1839 (1988); DeGasparo et al., J.
- inhibitor is provided in a pharmaceutical composition at about 1-5 mg/kg.
- amounts on the order of 10-100 mg/kg are utilized.
- the marmosets used for the study are depleted of sodium for two days by treatment with furosemide at 25 mg/kg/day po and a low sodium diet. A final dose of furosemide is administered one hour prior to anesthesia with Inactin at 120 mg/kg
- Blood pressure is measured from a catheter in the carotid artery via a Gould Stratham P23 pressure transducer and Lectromed M19 chart recorder.
- the jugular vein is cannulated for inhibitor injection and anesthetic infusion.
- Each animal serves as it own blood pressure control
- EDTA ethylenediaminetetra-acetic acid
- DTT dithiothreitol
- Synthetic HIV-1 proteinase [0.5 ⁇ g, obtained from Dr. Stephen Kent of The Scripps Research
- HIV substrate IV Bactetrate IV (Bachem Bioscience Inc.) at fixed concentrations. HIV Substrate IV has the sequence
- acetonitrile:water (3 percent trifluoroacetic acid; TFA) and contained 150 ⁇ M m-toluic acid which served as an HPLC standard. Quenched aliquots were injected into a reversed-phase HPLC (Hitachi instrument; VYDAC C 18 column No. 201TP54) and eluted with an isocratic mixture of 20 percent acetonitrile/80 percent water (0.1 percent TFA) flowing at 2.0 m./min. Reaction progress was monitored by following the increasing absorbance (peak height) of the substrate IV cleavage product detected at 254 nM. Inhibition studies indicated that one
- hydroxyethylamine isostere reported IC 50 values of several hundred to less than 0.4 nanomolar for compounds such as
- CBZ, t Bu, QC, PIC and DIQ are as previously defined.
- Those authors also reported differences in IC 50 values of about 2- to about 20-fold based upon the R or S stereochemistry of the hydroxyethylamine isostere, with the R isomers having greater activity.
- the peptide bond surrogate of the present invention is achiral and therefore does not present the R,S- isomeric problems of a hydroxyethylamine isostere.
- BOC-isoleucine was coupled to valine methyl ester hydrochloride using EDCI in the presence of N-methyl morpholine and HOBT in DMF/ethyl acetate at room temperature to form the N-blocked dipeptide methyl in about 95 percent yield.
- the BOC group was removed with TFA in methylene chloride at room temperature for about one hour, and the resulting dipeptide methyl ester was neutralized with sodium bicarbonate to provide the deprotected dipeptide methyl ester in about 98 percent yield.
- tripeptdie methyl ester in about 90 percent yield. Hydrogenolysis using Pd/C at room temperature for about three hours provided the title compound in about 90 percent yield. The overall yield was thus about 75 percent.
- BOC-(O-Bn) serine was coupled with leucine methyl ester hydrochloride as described before using a three-hour reaction time to provide the doubly blocked dipeptide methyl ester in about 95 percent yield.
- the BOC group was removed as discussed before and the resulting N-terminal amine was acetylated using acetic anhydride in pyridine at room
- the blocked dipeptide free acid was coupled with asparigine t-butyl ester hydrochloride as described before to provide the blocked tripeptide t-butyl ester in about 90 percent yield.
- the t-butyl ester was removed by reaction with TFA in methylene chloride at room temperature for about one hour to provide the title compound in about 90 percent yield.
- the overall yield here was about 66 percent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU34418/93A AU677949B2 (en) | 1992-01-09 | 1993-01-11 | Peptide linkage unit comprising methylene phosphinic acid |
JP51261393A JP3547432B2 (en) | 1992-01-09 | 1993-01-11 | Peptide linking units containing methylenephosphinic acid |
DE69319101T DE69319101T2 (en) | 1992-01-09 | 1993-01-11 | Linking group for peptides containing methylenephosphinic acid |
EP93903068A EP0629210B1 (en) | 1992-01-09 | 1993-01-11 | Peptide linkage unit comprising methylene phosphinic acid |
DK93903068T DK0629210T3 (en) | 1992-01-09 | 1993-01-11 | Peptide junction unit comprising methylene phosphinic acid |
US08/256,236 US5563121A (en) | 1992-01-09 | 1993-01-11 | Peptide linkage unit |
NO19942544A NO310919B1 (en) | 1992-01-09 | 1994-07-06 | Peptide Coupling Unit, Method for Using Them, and Peptides Containing a Coupling Unit, Pharmaceutical Preparation Containing Peptide and In vitro Inhibition of Aspartic Acid Proteinase Activity |
FI943282A FI943282A (en) | 1992-01-09 | 1994-07-08 | The peptide bond |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81935692A | 1992-01-09 | 1992-01-09 | |
US07/819,356 | 1992-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993014114A1 true WO1993014114A1 (en) | 1993-07-22 |
Family
ID=25227921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/000228 WO1993014114A1 (en) | 1992-01-09 | 1993-01-11 | Peptide linkage unit comprising methylene phosphinic acid |
Country Status (12)
Country | Link |
---|---|
US (1) | US5563121A (en) |
EP (1) | EP0629210B1 (en) |
JP (1) | JP3547432B2 (en) |
AT (1) | ATE167194T1 (en) |
AU (1) | AU677949B2 (en) |
CA (1) | CA2127295A1 (en) |
DE (1) | DE69319101T2 (en) |
DK (1) | DK0629210T3 (en) |
ES (1) | ES2119888T3 (en) |
FI (1) | FI943282A (en) |
NO (1) | NO310919B1 (en) |
WO (1) | WO1993014114A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078780A1 (en) * | 2003-03-04 | 2004-09-16 | Pepharm R&D Limited | Pharmaceutical composition containing l-seryl-l-leucine |
CN103525794A (en) * | 2012-07-06 | 2014-01-22 | 天津市国际生物医药联合研究院 | Method for separating and purifying inclusion body-type HIV-1 (human immunodeficiency virus-1) protease from prokaryotic system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0435059A1 (en) * | 1989-12-16 | 1991-07-03 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH634968A5 (en) * | 1977-04-01 | 1983-03-15 | Ciba Geigy Ag | HERBICIDAL AND PLANT GROWTH REGULATING AGENT CONTAINING A NEW PHOSPHINIC ACID OR ITS SALTS, ESTER, AMIDES OR HYDRAZIDES AND THEIR USE. |
-
1993
- 1993-01-11 ES ES93903068T patent/ES2119888T3/en not_active Expired - Lifetime
- 1993-01-11 DE DE69319101T patent/DE69319101T2/en not_active Expired - Fee Related
- 1993-01-11 AT AT93903068T patent/ATE167194T1/en not_active IP Right Cessation
- 1993-01-11 CA CA002127295A patent/CA2127295A1/en not_active Abandoned
- 1993-01-11 US US08/256,236 patent/US5563121A/en not_active Expired - Fee Related
- 1993-01-11 EP EP93903068A patent/EP0629210B1/en not_active Expired - Lifetime
- 1993-01-11 WO PCT/US1993/000228 patent/WO1993014114A1/en active IP Right Grant
- 1993-01-11 JP JP51261393A patent/JP3547432B2/en not_active Expired - Fee Related
- 1993-01-11 AU AU34418/93A patent/AU677949B2/en not_active Ceased
- 1993-01-11 DK DK93903068T patent/DK0629210T3/en active
-
1994
- 1994-07-06 NO NO19942544A patent/NO310919B1/en unknown
- 1994-07-08 FI FI943282A patent/FI943282A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0435059A1 (en) * | 1989-12-16 | 1991-07-03 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
Non-Patent Citations (4)
Title |
---|
JOURNAL OF ORGANIC CHEMISTRY vol. 55, no. 25, 7 December 1990, EASTON US pages 6268 - 6274 P.A. BARTLETT ET AL. 'Potent Inhibition of Pepsin and Penicillopepsin by Phosphorus-Containing Peptide Analogues' cited in the application * |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY vol. 114, no. 19, 9 September 1992, WASHINGTON, DC US pages 7604 - 7606 S. IKEDA ET AL. 'psi[PO2CH2N], a New Amide Bond Replacement: Potent, Slow-Binding Inhibition of the HIV Protease' * |
JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS vol. 1, 1 January 1990, LETCHWORTH GB pages 377 - 379 T. KISS ET AL. 'Copper(II) complexes of Ligands containing both Aminocarboxylate and Aminophosphinate Moieties' * |
PHOSPHORUS, SULFUR, AND SILICON vol. 45, 1989, pages 165 - 176 L. MAIER AND P.J. DIEL 'Organic Phosphorus compounds 871: Some Reactions of O-Ethyl-2-Chloroethylphosphonite' * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078780A1 (en) * | 2003-03-04 | 2004-09-16 | Pepharm R&D Limited | Pharmaceutical composition containing l-seryl-l-leucine |
CN103525794A (en) * | 2012-07-06 | 2014-01-22 | 天津市国际生物医药联合研究院 | Method for separating and purifying inclusion body-type HIV-1 (human immunodeficiency virus-1) protease from prokaryotic system |
Also Published As
Publication number | Publication date |
---|---|
FI943282A0 (en) | 1994-07-08 |
FI943282A (en) | 1994-09-08 |
JP3547432B2 (en) | 2004-07-28 |
AU677949B2 (en) | 1997-05-15 |
EP0629210A1 (en) | 1994-12-21 |
AU3441893A (en) | 1993-08-03 |
ES2119888T3 (en) | 1998-10-16 |
DE69319101D1 (en) | 1998-07-16 |
DE69319101T2 (en) | 1998-11-05 |
DK0629210T3 (en) | 1998-10-12 |
CA2127295A1 (en) | 1993-07-22 |
NO310919B1 (en) | 2001-09-17 |
NO942544L (en) | 1994-08-19 |
NO942544D0 (en) | 1994-07-06 |
US5563121A (en) | 1996-10-08 |
ATE167194T1 (en) | 1998-06-15 |
EP0629210B1 (en) | 1998-06-10 |
JPH07503013A (en) | 1995-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0155809B1 (en) | Renin inhibitors containing statine or derivatives thereof | |
AU636521B2 (en) | Inhibitors and substrates of thrombin | |
US6090786A (en) | Serine proteases, their activity and their synthetic inhibitors | |
Palacios et al. | β-phosphono-and phosphinopeptides derived from β-amino-phosphonic and phosphinic acids | |
WO1995029691A1 (en) | Proline phosphonate derivatives | |
CA2227516A1 (en) | Acylated oligopeptide derivatives having cell signal inhibiting activity | |
EP0813544B1 (en) | Bradykinin antagonist peptides incorporating n-substituted glycines | |
CA2170896A1 (en) | Kininogen inhibitors | |
EP0042291B1 (en) | Methods and compositions for preparation of h-arg-x-z-y-tyr-r | |
US4609643A (en) | Renin inhibitors, treatments and dipeptide synthesis | |
JPH10182613A (en) | Tetraphydroisoquinoline derivative | |
EP0629210B1 (en) | Peptide linkage unit comprising methylene phosphinic acid | |
EP0040149B1 (en) | Oligopeptides with specific inhibiting properties of collagen induced aggregation, process for preparing the same and pharmaceutical compositions containing them | |
Antonaccio et al. | Enzyme inhibitors of the renin-angiotensin system | |
US20060183691A1 (en) | Anti-hypertensive molecules and process for preparation thereof | |
WO1993009134A1 (en) | Phosphonamidate ester-containing pseudopeptides | |
HU181008B (en) | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position | |
US4191753A (en) | Anti-hypertensive peptide analogs | |
JPH0952900A (en) | Novel peptide derivative usable as zinc endopeptidase 24-15 inhibitor | |
US4920144A (en) | Derivatives of bicyclic amino acids, agents containing them and their use as hypotensives | |
WO1991005555A2 (en) | N-acyl peptide metalloendopeptidase inhibitors and methods of using same | |
WO1994001126A1 (en) | Compounds for inhibition of proteolysis | |
IE850640L (en) | Renin inhibitors containing statine | |
WO1990009172A1 (en) | Phosphorus containing renin inhibitors | |
CHRISTINE | Peptide Hormones and Other Biologically Active Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08256236 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2127295 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 943282 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993903068 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1993903068 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993903068 Country of ref document: EP |